Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127825657> ?p ?o ?g. }
- W2127825657 endingPage "103" @default.
- W2127825657 startingPage "94" @default.
- W2127825657 abstract "Background/Aims Men with signs of benign prostatic hyperplasia (BPH) may experience lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, intermittence, nocturia, straining, incomplete emptying or a weak urinary stream. The effective management of LUTS suggestive of BPH (BPH-LUTS) requires careful consideration of several factors, including the severity of a patient's symptoms, concurrent or other coexisting medical conditions, the ability to improve symptoms and impact quality of life (QOL), as well as the potential side effects of available treatment options. Several clinical studies have assessed phosphodiesterase type 5 (PDE5) inhibitors in reducing LUTS; however, tadalafil is the only PDE5 inhibitor approved for the treatment of signs and symptoms of BPH, as well as in men with both erectile dysfunction (ED) and the signs and symptoms of BPH. This review examined articles that assessed tadalafil in patients with signs and symptoms of BPH, with or without erectile dysfunction (ED), which led to regulatory approval in the United States and Europe. Results In dose-ranging and confirmatory studies, results demonstrate that tadalafil significantly improved total International Prostate Symptom Score (IPSS) following 12 weeks of treatment with once daily tadalafil 5 mg. Statistically significant improvements in Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS QOL and International Index of Erectile Function (IIEF) were also observed. Improvement in urinary symptoms occurred regardless of age, previous treatment with an α1-adrenergic blocker, BPH-LUTS severity at baseline or ED status. Conclusions While tadalafil is most frequently recognised as a standard treatment option for men with ED, it also represents a well-tolerated and effective treatment option in men with moderate to severe BPH-LUTS." @default.
- W2127825657 created "2016-06-24" @default.
- W2127825657 creator A5019825677 @default.
- W2127825657 creator A5026692318 @default.
- W2127825657 creator A5080568202 @default.
- W2127825657 creator A5081650411 @default.
- W2127825657 date "2013-12-17" @default.
- W2127825657 modified "2023-09-23" @default.
- W2127825657 title "Tadalafil - a therapeutic option in the management of BPH-LUTS" @default.
- W2127825657 cites W1518162929 @default.
- W2127825657 cites W1590209850 @default.
- W2127825657 cites W1793951671 @default.
- W2127825657 cites W1947843794 @default.
- W2127825657 cites W1962507201 @default.
- W2127825657 cites W1964683861 @default.
- W2127825657 cites W1966649210 @default.
- W2127825657 cites W1982562788 @default.
- W2127825657 cites W1986031402 @default.
- W2127825657 cites W1994414216 @default.
- W2127825657 cites W1995256786 @default.
- W2127825657 cites W1997605348 @default.
- W2127825657 cites W2006615433 @default.
- W2127825657 cites W2007681156 @default.
- W2127825657 cites W2018377518 @default.
- W2127825657 cites W2020539470 @default.
- W2127825657 cites W2023252283 @default.
- W2127825657 cites W2050093658 @default.
- W2127825657 cites W2070170982 @default.
- W2127825657 cites W2072553225 @default.
- W2127825657 cites W2073978463 @default.
- W2127825657 cites W2074093603 @default.
- W2127825657 cites W2074917601 @default.
- W2127825657 cites W2078469638 @default.
- W2127825657 cites W2086003873 @default.
- W2127825657 cites W2105669626 @default.
- W2127825657 cites W2120592220 @default.
- W2127825657 cites W2164856644 @default.
- W2127825657 cites W2168839555 @default.
- W2127825657 cites W2229746530 @default.
- W2127825657 cites W2807400090 @default.
- W2127825657 doi "https://doi.org/10.1111/ijcp.12305" @default.
- W2127825657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24341303" @default.
- W2127825657 hasPublicationYear "2013" @default.
- W2127825657 type Work @default.
- W2127825657 sameAs 2127825657 @default.
- W2127825657 citedByCount "18" @default.
- W2127825657 countsByYear W21278256572014 @default.
- W2127825657 countsByYear W21278256572015 @default.
- W2127825657 countsByYear W21278256572016 @default.
- W2127825657 countsByYear W21278256572017 @default.
- W2127825657 countsByYear W21278256572018 @default.
- W2127825657 countsByYear W21278256572019 @default.
- W2127825657 countsByYear W21278256572020 @default.
- W2127825657 countsByYear W21278256572021 @default.
- W2127825657 countsByYear W21278256572023 @default.
- W2127825657 crossrefType "journal-article" @default.
- W2127825657 hasAuthorship W2127825657A5019825677 @default.
- W2127825657 hasAuthorship W2127825657A5026692318 @default.
- W2127825657 hasAuthorship W2127825657A5080568202 @default.
- W2127825657 hasAuthorship W2127825657A5081650411 @default.
- W2127825657 hasConcept C121608353 @default.
- W2127825657 hasConcept C126322002 @default.
- W2127825657 hasConcept C126894567 @default.
- W2127825657 hasConcept C159110408 @default.
- W2127825657 hasConcept C2776235491 @default.
- W2127825657 hasConcept C2776547966 @default.
- W2127825657 hasConcept C2777333188 @default.
- W2127825657 hasConcept C2779478474 @default.
- W2127825657 hasConcept C2779929075 @default.
- W2127825657 hasConcept C2779951463 @default.
- W2127825657 hasConcept C2780435053 @default.
- W2127825657 hasConcept C2780816001 @default.
- W2127825657 hasConcept C71924100 @default.
- W2127825657 hasConcept C74534348 @default.
- W2127825657 hasConcept C77411442 @default.
- W2127825657 hasConceptScore W2127825657C121608353 @default.
- W2127825657 hasConceptScore W2127825657C126322002 @default.
- W2127825657 hasConceptScore W2127825657C126894567 @default.
- W2127825657 hasConceptScore W2127825657C159110408 @default.
- W2127825657 hasConceptScore W2127825657C2776235491 @default.
- W2127825657 hasConceptScore W2127825657C2776547966 @default.
- W2127825657 hasConceptScore W2127825657C2777333188 @default.
- W2127825657 hasConceptScore W2127825657C2779478474 @default.
- W2127825657 hasConceptScore W2127825657C2779929075 @default.
- W2127825657 hasConceptScore W2127825657C2779951463 @default.
- W2127825657 hasConceptScore W2127825657C2780435053 @default.
- W2127825657 hasConceptScore W2127825657C2780816001 @default.
- W2127825657 hasConceptScore W2127825657C71924100 @default.
- W2127825657 hasConceptScore W2127825657C74534348 @default.
- W2127825657 hasConceptScore W2127825657C77411442 @default.
- W2127825657 hasIssue "1" @default.
- W2127825657 hasLocation W21278256571 @default.
- W2127825657 hasLocation W21278256572 @default.
- W2127825657 hasOpenAccess W2127825657 @default.
- W2127825657 hasPrimaryLocation W21278256571 @default.
- W2127825657 hasRelatedWork W1559582992 @default.
- W2127825657 hasRelatedWork W2028938466 @default.
- W2127825657 hasRelatedWork W2046101516 @default.